Atlas Trials

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Clinical trial NCT03316599 · COMPLETED

Trial details

NCT number
NCT03316599
Sponsor
Dana-Farber Cancer Institute
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2018-01-17
Primary completion
2020-10-10
Enrollment
26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.